STOKE THERAPEUTICS AND BIOGEN ANNOUNCE PRESENTATIONS OF CLINICAL DATA FROM STUDIES OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME, AT THE 16TH EUROPEAN EPILEPSY CONGRESS (EEC)

Reuters · 2d ago

Please log in to view news